ABO and Alzheimer disease: This report details clinical safety (including ARIA-E), pharmacokinetics, and several exploratory pharmacodynamic measures, including central target engagement (sabirnetug bound to AβO), from the INTERCEPT-AD Phase 1 study of sabirnetug in participants with early symptomatic AD (mild cognitive impairment [MCI] or mild dementia due to AD).